CHARGED ALPHA
Stock Analysis
RDY Unclassified Latest YouTube: Q1 FY2027

RDY

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Latest earnings video

Dr. Reddy’s Stock (RDY): Profit Crashed 69% to a 52-Week Low — Overreaction, or Broken Engine?

Library coverage

Episodes tracked
1
Episodes linked
1
Latest video
Q1 FY2027
Podcast available
Yes
Current price
$11.80
+0.25 (+2.16%)
Trailing / Forward P/E
28.78x
Forward: 18.31x
Market cap / Volume
Volume:
Revenue / Earnings Growth
-5.6%
Earnings: -68.7%
Margins
2.4% op
Gross: 50.2% · Net: 10.0%
Balance sheet
Debt / Equity: 20.3
52-week range / Beta
$11.36 - $15.67
Beta: 0.26
Analyst target
$14.14
Upside: 19.8%
Cash / shareholder return
Dividend yield: 0.70%

Company context

Industry: Drug Manufacturers - Specialty & Generic
Country: India
Employees:
Price to book: 14.72x
Return on equity:
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Price chart

Market context for RDY

Competitive view

RDY vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

RDY latest YouTube video thumbnail YouTube
RDY
RDY
Latest video
Q1 FY2027
Growth profile looks mature or currently muted, which can cap multiple expansion unless execution improves.
Profitability is serviceable, but it does not obviously dominate peers on margin or cash conversion alone.
Valuation sits in a middle zone where future upside likely depends more on quarterly execution than on multiple re-rating alone.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Danaher Corporation latest YouTube video thumbnail YouTube
Danaher Corporation
DHR
Latest video
Q2 2026
Growth profile looks strong right now, with above-average top-line and/or earnings momentum.
Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.
Valuation sits in a middle zone where future upside likely depends more on quarterly execution than on multiple re-rating alone.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
ADBE latest YouTube video thumbnail YouTube
ADBE
ADBE
Latest video
Q2 FY2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Market Cap
More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.
RDY
$9.83B
RDY
DHR
$135.32B
Danaher Corporation
ADBE
$84.34B
ADBE
Trailing P/E
Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.
RDY
28.8x
RDY
DHR
34.3x
Danaher Corporation
ADBE
12.1x
ADBE
Forward P/E
Forward P/E is often a better read on what investors are paying for the next year of earnings power.
RDY
18.3x
RDY
DHR
20.8x
Danaher Corporation
ADBE
7.7x
ADBE
Revenue Growth
Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.
RDY
-5.6%
RDY
DHR
5.5%
Danaher Corporation
ADBE
12.7%
ADBE
Earnings Growth
Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.
RDY
-68.7%
RDY
DHR
59.7%
Danaher Corporation
ADBE
7.9%
ADBE
Operating Margin
Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.
RDY
2.4%
RDY
DHR
19.8%
Danaher Corporation
ADBE
35.3%
ADBE
Gross Margin
Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.
RDY
50.2%
RDY
DHR
58.8%
Danaher Corporation
ADBE
89.4%
ADBE
Net Margin
Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.
RDY
10.0%
RDY
DHR
15.9%
Danaher Corporation
ADBE
28.7%
ADBE
Return on Equity
ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.
RDY
RDY
DHR
7.6%
Danaher Corporation
ADBE
63.0%
ADBE
Free Cash Flow Yield
Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.
RDY
RDY
DHR
3.2%
Danaher Corporation
ADBE
10.9%
ADBE
Debt to Equity
Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.
RDY
20.33x
RDY
DHR
52.97x
Danaher Corporation
ADBE
61.44x
ADBE
Current Ratio
A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.
RDY
RDY
DHR
1.65x
Danaher Corporation
ADBE
0.75x
ADBE
Beta
Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.
RDY
0.26
RDY
DHR
0.82
Danaher Corporation
ADBE
1.43
ADBE
Dividend Yield
Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.
RDY
0.7%
RDY
DHR
0.8%
Danaher Corporation
ADBE
ADBE
Analyst Upside
Higher analyst upside suggests the Street still sees room between current price and consensus fair value.
RDY
19.8%
RDY
DHR
18.8%
Danaher Corporation
ADBE
27.1%
ADBE

Related research

Non-quarter videos featuring RDY

Special-topic videos, explainers, and shorts connected to this ticker.

All Research Sections
Shorts and Clips 2026-07-22

Dr. Reddy's CRASHED 69% — Overreaction or Broken Engine? #RDY #stocks #investing

A fast Charged Alpha clip pointing viewers into the latest earnings coverage.

Episode timeline

Episode archive for RDY

Each row is one earnings episode with every verified platform link available.

Q1 FY2027
Episode live
Published youtube podcast complete
Dr. Reddy’s Stock (RDY): Profit Crashed 69% to a 52-Week Low — Overreaction, or Broken Engine?
Quarterly earnings-analysis entry for RDY. Use the links on the right to open the video or podcast episode.